When was Primorigen founded?

Primorigen was founded in 2005 and raised its 1st funding round 1 year after it was founded.

Where is Primorigen located?

Primorigen is headquartered in Madison, United States.

How many employees does Primorigen have?

As of Jul 01, 2024, the latest employee count at Primorigen is 11 - 50.

Is Primorigen a funded company?

Primorigen is a funded company, having raised a total of $2.5M across 19 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 21, 2006.

When was the latest funding round of Primorigen?

Primorigen's latest funding was a $***** Grant (prize money) round on Apr 01, 2015, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.23B in funding in 2026 to date.

Where does Primorigen rank among its competitors?

Primorigen ranks 80th amongst 379 active competitors, of which 41 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Abselion, which secured $8.41M in Oct, 2024.

Who are the top competitors of Primorigen?

Primorigen's top competitors include Siemens Healthineers, Illumina and Quanterix. Among them, Abselion secured the most recent funding round in October, 2024.

Primorigen - 2026 Company Profile, Team, Funding & Competitors

Primorigen is an acquired company based in Madison (United States), founded in 2005. It operates as an A stem cell assay, tool & reagent company. Primorigen has raised $2.5M in funding. The company has 379 active competitors, including 41 funded and 54 that have exited. Its top competitors include companies like Siemens Healthineers, Illumina and Quanterix.

Company Details

Primorigen Biosciences is committed to developing innovative and economical high-throughput protein and cell based assay systems for cellular characterization and preclinical research. Existing products include Vitronectin XF™, a recombinant human protein that offers a defined, xenobiotic-free substrate for pluripotent cell proliferation and differentiation, MesoTotal™ a high efficiency, high yield hematopoietic stem cell differentiation medium, high quality monoclonal antibodies validated for stem cell characterization--including flow cytometry, human cytokines and growth factors, and others. Products in development include next-generation matrices and related technologies for stem cell expansion, differentiation and media reduction, cost-effective systems for consistent, simple industrial scale stem cell production, HTS plates populated with stem cell derived phenotypes for screening environmental toxins and other compounds, and other new products. In addition, Primorigen’s proprietary Spot on Dots™ frameless microarray platform provides a versatile, high-throughput substrate for building quantitative assays to detect proteins of interest.

Website: primorigen.com
Social

Key Metrics

Founded Year

2005

Location

Madison, United States

Stage

Acquired

Total Funding

$2.5M in 19 rounds

Latest Funding Round

Grant (prize money), Apr 01, 2015, $*****

Investors

NIH & 2 more

Ranked

80^th among 379 active competitors

Employee Count

11 - 50 as on Jul 01, 2024

Similar Companies

Siemens Healthineers & 426 more

Exit Details

Acquired by Nucleus Biologics (Aug 06, 2019)

View Primorigen's full profile

Primorigen got acquired by Nucleus Biologics on Aug 06, 2019.

Click here to take a look at Primorigen's acquisition in detail

Primorigen has raised a total funding of $2.5M over 19 rounds. Its first funding round was on Oct 21, 2006. Its latest funding round was a Grant (prize money) round on Apr 01, 2015 for $*****. 1 investor participated in its latest round. Primorigen has 3 institutional investors.

Here is the list of recent funding rounds of Primorigen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2015	3379388	Grant (prize money)	5270327	6078021	8673938	2561344
Apr 01, 2014	7609316	Grant (prize money)	7071705	7487598	3978586	HHS
Sep 30, 2013	2618420	Grant (prize money)	8162391	8387634	1248671	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Primorigen's funding rounds and investors

Primorigen's employee count trend

Primorigen has 11 - 50 employees as of Jul 24. Here is Primorigen's employee count trend over the years:

Uncover Primorigen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Primorigen include Siemens Healthineers, Illumina and Quanterix. Here is the list of Top 10 competitors of Primorigen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Siemens Healthineers 2017, Forchheim (Germany), Public	Provider of medical imaging laboratory diagnostics and clinical digital solutions	-	Qatar Investment Authority, Skyviews Life Science ... & 3 others	75/100
2nd	Illumina 1993, San Diego (United States), Public	Developer of technologies for analysis of genetic variation and function	$28M	Chevron Technology Ventures, Dow Chemical Company ... & 32 others	71/100
3rd	Quanterix 2007, Cambridge (United States), Public	Developer of assay kits for ultra-sensitive biomarker detection	$99.5M	T. Rowe Price, Novalis LifeSciences & 15 others	71/100
4th	BioLife Solutions 1987, Bothell (United States), Acquired	Developer of cell and gene therapies with the integrity of a single cell	-	-	67/100
5th	Biocare Medical 1997, Concord (United States), Acquired	Manufacturer of primary antibodies and instruments for immunohistochemistry applications	$85M	Excellere Partners, GHO Capital Partners & 3 others	65/100
6th	MGI 2016, Shenzhen (China), Series B	Provider of gene sequencing instruments, reagents, equipment, and related products	$1B	Guotai Junan Securities, CoStone Capital ... & 13 others	63/100
7th	Bio-Techne 1981, Minneapolis (United States), Acquired	Developer of biotech reagents, instruments and clinical diagnostic products	-	HHS	59/100
8th	Abselion 2018, Cambridge (United Kingdom), Series A	Provider of a benchtop instrument for protien research	$12.6M	University of Cambridge, M Ventures & 13 others	59/100
9th	Applied BioCode 2008, Santa Fe Springs (United States), Public	Developer of assay testing kits and instruments for in vitro diagnostics, research, and other industrial applications	$20.3M	ID Ventures America, TPTF & 4 others	59/100
10th	Bio Rad 1952, Hercules (United States), Public	Portfolio of products and services for life science research and clinical diagnostic markets	-	Bellevue Healthcare Trust, SMB Capital Partners ... & 3 others	58/100
80th	Primorigen 2005, Madison (United States), Acquired	A stem cell assay, tool & reagent company	$2.5M	NIH, Louisiana Fund & 1 others	33/100